22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › ARBUTUS BIOPHARMA CORP. › 2024-2025

ARBUTUS BIOPHARMA CORP. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ARBUTUS BIOPHARMA CORP.’s Form 8-K, filed May 23, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 7Ballot items
  • 137Asset managers, any item
  • 998Fund votes
  • May 21, 2025Meeting date

Results at a glance

Meeting of May 21, 2025: 7 items on ARBUTUS BIOPHARMA CORP.’s Form 8-K, filed May 23, 2025: 2 approved · 5 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Two Seas Capital LP (13F, 4.1%, as of September 30, 2026) · Rubric Capital (13F, 1.7%, as of September 30, 2026)

Explore ARBUTUS BIOPHARMA CORP. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ARBUTUS BIOPHARMA CORP.

These tallies are ARBUTUS BIOPHARMA CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 23, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ARBUTUS BIOPHARMA CORP. — official shareholder meeting results, meeting held May 21, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Lindsay Androski, JD, MBA, CFA 123,784,223---- 6,331,63428,231,130 95%Passed (calculated)—
Elect Director: Robert Alan Beardsley 124,837,983---- 5,277,87428,231,130 96%Passed (calculated)—
Elect Director: Joseph Bishop 122,059,590---- 8,056,26728,231,130 94%Passed (calculated)—
Elect Director: Matthew Gline 122,656,045---- 7,459,81228,231,130 94%Passed (calculated)—
Elect Director: Anuj Hasija 124,821,361---- 5,294,49628,231,130 96%Passed (calculated)—
2. Approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Company's Management Proxy Circular and Proxy Statement for the Meeting filed with the Securities and Exchange Commission on April 4, 2025 122,791,7496,976,561347,547 --28,231,130 95%Approved—
3. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 157,702,833486,002158,152 ---- 99.7%Approved—

Source: ARBUTUS BIOPHARMA CORP., Form 8-K, filed with the SEC on May 23, 2025 — read the filing on EDGAR.

How asset managers voted at the ARBUTUS BIOPHARMA CORP. 2024-2025 meeting

137 asset managers disclosed a vote on at least one ARBUTUS BIOPHARMA CORP. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Anuj Hasija

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 124,821,361WITHHELD: 5,294,496
Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Anuj Hasija

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Anuj Hasija”): 124,821,361 for, 5,294,496 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 27,883,253 for.

FOR
FOR: 27,883,253
Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,631,0060 00For
Morgan Stanley6,930,2430 00For
BlackRock5,196,3830 00For
Fidelity2,236,8420 00For
Equitable1,452,5240 00For
Charles Schwab1,196,1920 00For
State Street643,5800 00For
Aberdeen342,3790 00For
TIAA311,1730 00For
Lincoln Financial195,5760 00For
Global X87,2170 00For
Goldman Sachs76,1520 00For
Northern Trust75,3330 00For
ProShares59,3470 00For
John Hancock55,6370 00For
Pacific Life48,2210 00For
ETFis Series Trust I43,2090 00For
Voya40,7200 00For
Invesco34,9970 00For
Direxion Shares ETF Trust32,5530 00For
Bridge Builder Trust32,1230 00For
DWS21,1530 00For
QUANTITATIVE MASTER SERIES LLC21,0610 00For
Nationwide21,0490 00For
Columbia Threadneedle17,8010 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Elect Director: Joseph Bishop

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 122,059,590WITHHELD: 8,056,267
Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Joseph Bishop

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Joseph Bishop”): 122,059,590 for, 8,056,267 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 26,569,049 for, 1,314,204 withheld.

FOR
FOR: 26,569,049WITHHOLD: 1,314,204
Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,631,0060 00For
Morgan Stanley6,930,2430 00For
BlackRock5,196,3830 00For
Fidelity2,222,7470 014,095For
Equitable1,452,5240 00For
Charles Schwab00 01,196,192Withhold
State Street643,5800 00For
Aberdeen342,3790 00For
TIAA311,1730 00For
Lincoln Financial195,5760 00For
Global X00 087,217Withhold
Goldman Sachs76,1520 00For
Northern Trust75,3330 00For
ProShares59,3470 00For
John Hancock55,6370 00For
Pacific Life48,2210 00For
ETFis Series Trust I43,2090 00For
Voya40,7200 00For
Invesco34,9970 00For
Direxion Shares ETF Trust32,5530 00For
Bridge Builder Trust32,1230 00For
DWS21,1530 00For
QUANTITATIVE MASTER SERIES LLC21,0610 00For
Nationwide21,0490 00For
Columbia Threadneedle17,8010 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Elect Director: Lindsay Androski, JD, MBA, CFA

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 123,784,223WITHHELD: 6,331,634
Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Lindsay Androski, JD, MBA, CFA

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Lindsay Androski, JD, MBA, CFA”): 123,784,223 for, 6,331,634 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 27,841,928 for, 41,325 withheld.

FOR
FOR: 27,841,928WITHHOLD: 41,325
Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,631,0060 00For
Morgan Stanley6,930,2430 00For
BlackRock5,196,3830 00For
Fidelity2,236,8420 00For
Equitable1,452,5240 00For
Charles Schwab1,196,1920 00For
State Street643,5800 00For
Aberdeen342,3790 00For
TIAA311,1730 00For
Lincoln Financial195,5760 00For
Global X87,2170 00For
Goldman Sachs76,1520 00For
Northern Trust75,3330 00For
ProShares59,3470 00For
John Hancock55,6370 00For
Pacific Life48,2210 00For
ETFis Series Trust I43,2090 00For
Voya00 040,720Withhold
Invesco34,9970 00For
Direxion Shares ETF Trust32,5530 00For
Bridge Builder Trust32,1230 00For
DWS21,1530 00For
QUANTITATIVE MASTER SERIES LLC21,0610 00For
Nationwide21,0490 00For
Columbia Threadneedle17,8010 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Elect Director: Matthew Gline

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 122,656,045WITHHELD: 7,459,812
Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Matthew Gline

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Matthew Gline”): 122,656,045 for, 7,459,812 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 26,569,049 for, 1,314,204 withheld.

FOR
FOR: 26,569,049WITHHOLD: 1,314,204
Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,631,0060 00For
Morgan Stanley6,930,2430 00For
BlackRock5,196,3830 00For
Fidelity2,222,7470 014,095For
Equitable1,452,5240 00For
Charles Schwab00 01,196,192Withhold
State Street643,5800 00For
Aberdeen342,3790 00For
TIAA311,1730 00For
Lincoln Financial195,5760 00For
Global X00 087,217Withhold
Goldman Sachs76,1520 00For
Northern Trust75,3330 00For
ProShares59,3470 00For
John Hancock55,6370 00For
Pacific Life48,2210 00For
ETFis Series Trust I43,2090 00For
Voya40,7200 00For
Invesco34,9970 00For
Direxion Shares ETF Trust32,5530 00For
Bridge Builder Trust32,1230 00For
DWS21,1530 00For
QUANTITATIVE MASTER SERIES LLC21,0610 00For
Nationwide21,0490 00For
Columbia Threadneedle17,8010 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Elect Director: Robert Alan Beardsley

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 124,837,983WITHHELD: 5,277,874
Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Robert Alan Beardsley

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Robert Alan Beardsley”): 124,837,983 for, 5,277,874 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 27,883,253 for.

FOR
FOR: 27,883,253
Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,631,0060 00For
Morgan Stanley6,930,2430 00For
BlackRock5,196,3830 00For
Fidelity2,236,8420 00For
Equitable1,452,5240 00For
Charles Schwab1,196,1920 00For
State Street643,5800 00For
Aberdeen342,3790 00For
TIAA311,1730 00For
Lincoln Financial195,5760 00For
Global X87,2170 00For
Goldman Sachs76,1520 00For
Northern Trust75,3330 00For
ProShares59,3470 00For
John Hancock55,6370 00For
Pacific Life48,2210 00For
ETFis Series Trust I43,2090 00For
Voya40,7200 00For
Invesco34,9970 00For
Direxion Shares ETF Trust32,5530 00For
Bridge Builder Trust32,1230 00For
DWS21,1530 00For
QUANTITATIVE MASTER SERIES LLC21,0610 00For
Nationwide21,0490 00For
Columbia Threadneedle17,8010 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 122,791,749AGAINST: 6,976,561

Prior year: 88.0% for (May 22, 2024 meeting) ▲ 6.6 pts

Details: description as filed, official tally, votes by 137 asset managers

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular; and

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“2. Approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Company's Management Proxy Circular and Proxy Statement for the Meeting filed with the Securities ”): 122,791,749 for, 6,976,561 against — passed, per its Form 8-K filed May 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(2) approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Company's Management Proxy Circular and Proxy Statement for the Meeting filed with the Securities and Exchange Commission on April 4, 2025 (the "Proxy Statement/Circular")”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 38 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in ” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,631,0060 00For
Morgan Stanley6,930,2430 00For
BlackRock5,196,3830 00For
Fidelity2,236,8420 00For
Equitable1,452,5240 00For
Charles Schwab1,196,1920 00For
State Street643,5800 00For
Aberdeen0342,379 00Against
TIAA311,1730 00For
Saba Capital Income & Opportunities Fund188,51020,341 01,017Mixed
Lincoln Financial195,5760 00For
Saba Capital Income & Opportunities Fund II105,90711,427 0572Mixed
Global X87,2170 00For
Goldman Sachs76,1520 00For
Northern Trust75,3330 00For
ProShares59,3470 00For
John Hancock55,6370 00For
Pacific Life48,2210 00For
ETFis Series Trust I43,2090 00For
Voya40,7200 00For
Invesco034,997 00Against
Direxion Shares ETF Trust32,5530 00For
Bridge Builder Trust32,1230 00For
DWS21,1530 00For
QUANTITATIVE MASTER SERIES LLC21,0610 00For

Fund voting reports, all 38 managers: 27,786,808 for, 422,630 against, 1,589 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 113 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in ” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Morgan Stanley22,119,9800 00For
Whitefort Capital Management, LP13,307,9670 00For
Two Seas Capital LP9,272,5550 00For
BlackRock3,295,58754,827 00For
Woodline Partners LP2,552,9420 00For
GEODE CAPITAL MANAGEMENT, LLC2,195,7110 00For
State Street2,155,3681,481 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.1,575,9410 00For
Rangeley Capital, LLC1,349,0000 00For
Charles Schwab1,196,4320 00For
Saba Capital Management, L.P.925,41631,768 1,5890For
Rubric Capital Management LP827,3280 00For
Northern Trust724,2420 00For
Hudson Bay Capital Management LP484,4610 00For
Vanguard480,5130 00For
ADAR1 Capital Management, LLC454,9200 00For
Wellington370,5380 00For
Aberdeen0342,379 00Against
Nuveen313,3070 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC294,7580 00For
UBS0267,277 00Against
MELLON INVESTMENTS Corp214,0290 00For
KENNEDY CAPITAL MANAGEMENT LLC147,86033,734 00Mixed
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM122,0420 00For
AllianceBernstein120,2400 00For

Institutional-manager reports, all 113 managers: 65,673,637 for, 962,139 against, 1,824 abstained. Showing the 25 largest; every one is in the interactive database (link above).

To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the…

Official resultAUDIT-RELATEDReported outcome: Approved

99.7% Approved · of votes cast

FOR 99.7%
FOR: 157,702,833AGAINST: 486,002
Details: description as filed, official tally, votes by 38 asset managers

Description as filed by funds: To approve the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“3. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 157,702,833 for, 486,002 against — passed, per its Form 8-K filed May 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(3) approved the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 38 asset managers below reported 28,209,799 for, 1,081 against, 148 withheld.

FOR
FOR: 28,209,799AGAINST: 1,081WITHHOLD: 148
Largest asset managers voting on “To approve the appointment of Ernst & Young LLP as our independent registered public accounting firm for the f” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,631,0060 00For
Morgan Stanley6,930,2430 00For
BlackRock5,196,3830 00For
Fidelity2,236,8420 00For
Equitable1,452,5240 00For
Charles Schwab1,196,1920 00For
State Street643,5800 00For
Aberdeen342,3790 00For
TIAA311,1730 00For
Saba Capital Income & Opportunities Fund209,082692 095For
Lincoln Financial195,5760 00For
Saba Capital Income & Opportunities Fund II117,464389 053For
Global X87,2170 00For
Goldman Sachs76,1520 00For
Northern Trust75,3330 00For
ProShares59,3470 00For
John Hancock55,6370 00For
Pacific Life48,2210 00For
ETFis Series Trust I43,2090 00For
Voya40,7200 00For
Invesco34,9970 00For
Direxion Shares ETF Trust32,5530 00For
Bridge Builder Trust32,1230 00For
DWS21,1530 00For
QUANTITATIVE MASTER SERIES LLC21,0610 00For

Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).

Largest ARBUTUS BIOPHARMA CORP. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 191,527,129 shares outstanding at the time of that meeting.

Fund voting reports: top ARBUTUS BIOPHARMA CORP. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of our named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 4.51%
2Morgan Stanley 3.62%
3BlackRock 2.71%
4Fidelity 1.17%
5Equitable 0.76%
6Charles Schwab 0.62%
7State Street 0.34%
8Aberdeen 0.18%
9TIAA 0.16%
10Saba Capital Income & Opportunities Fund 0.11%
Institutional-manager reports: top ARBUTUS BIOPHARMA CORP. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of our named executive officers…”, 2024-2025
#Asset manager % of shares outstanding
1Morgan Stanley 11.55%
2Whitefort Capital Management, LP 6.95%
3Two Seas Capital LP 4.84%
4BlackRock 1.75%
5Woodline Partners LP 1.33%
6GEODE CAPITAL MANAGEMENT, LLC 1.15%
7State Street 1.13%
8ADAGE CAPITAL PARTNERS GP, L.L.C. 0.82%
9Rangeley Capital, LLC 0.70%
10Charles Schwab 0.62%

Reported ARBUTUS BIOPHARMA CORP. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ARBUTUS BIOPHARMA CORP. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Matthew Gline38,847,462 20.28%Proxy statement (DEF 14A), proxy filed April 4, 2025
Roivant Sciences Ltd.38,847,462 20.28%Schedule 13D, filed February 25, 2025
Morgan Stanley25,910,337 13.53%Schedule 13G, filed February 11, 2026
Two Seas Capital LP18,557,543 9.69%Schedule 13G, filed May 15, 2026
Whitefort Capital Master Fund, LP15,794,261 8.25%Schedule 13D, filed April 28, 2026
Whitefort Capital Management, LP13,307,967 6.95%Proxy statement (DEF 14A), proxy filed April 4, 2025
BlackRock12,766,622 6.67%Form 13F, quarter ended March 31, 2025
Vanguard Group8,953,823 4.67%Form 13F, quarter ended March 31, 2025
State Street4,363,507 2.28%Form 13F, quarter ended March 31, 2025
Michael J. McElhaugh2,649,793 1.38%Proxy statement (DEF 14A), proxy filed April 4, 2025

Percentages above are of 191,527,129 shares outstanding, as reported by ARBUTUS BIOPHARMA CORP. on its Form 10-Q dated May 12, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ARBUTUS BIOPHARMA CORP.'s shareholder meeting held May 21, 2025, in the 2024-2025 proxy season, 137 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 998 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — ARBUTUS BIOPHARMA CORP.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ARBUTUS BIOPHARMA CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 23, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARBUTUS BIOPHARMA CORP.’s 10-Q dated May 12, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ARBUTUS BIOPHARMA CORP. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “ARBUTUS BIOPHARMA (ABUS) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/arbutus-biopharma-corp/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.